Table 2.
Biological Markers
| Marker | Patients, Total N = 117 | Controls, Total N = 106 | Statistics | df | P-Value |
|---|---|---|---|---|---|
| NFκB -act- | 12.79±22.24* (n = 53) | 4.36±3.28 (n = 35) | U = 612.0 | — | .007 |
| iNOS -WBc- | 125.36±49.71* (n = 91) | 96.60±40.50 (n = 88) | U = 2585.5 | — | <.001 |
| COX2 -WBc- | 145.28±145.50* (n = 90) | 94.58±61.92 (n = 88) | U = 2517.0 | — | <.001 |
| NO− 2 -sol- | 14.65±5.90 (n = 50) | 12.75±4.67 (n = 61) | U = 1270.0 | — | .131 |
| PGE2 -sol- | 524.89±739.41 (n = 111) | 373.35±264.95 (n = 104) | U = 5522.5 | — | .584 |
| TBARS -sol- | 3.49±3.52 (n = 105) | 2.68±2.69 (n = 104) | U = 4748.5 | — | .109 |
| Hcy -sol- | 16.30±17.41 (n = 71) | 9.87±6.86 (n = 41) | U = 1194.0 | — | .114 |
| IκBα -WBc- | 84.81±47.63* (n = 91) | 103.66±47.13 (n = 88) | U = 2922.0 | — | .002 |
| 15dPGJ2 -sol- | 571.32±154.63* (n = 108) | 618.87±158.42 (n = 104) | U = 4737.0 | — | .049 |
| PPAR -WBn- | 77.64±32.91* (n = 14) | 103.12±27.92 (n = 16) | t = 2.30 | 28 | .029 |
| PPAR -act- | 1.39±0.96* (n = 71) | 1.88±1.45 (n = 41) | U = 2532.5 | — | .005 |
Note: Mean differences (SD) on biomarkers levels between FEP and controls. Two-tailed t test was assessed for PPARγ expression because its distribution meets the assumption of normality in the Kolmogorov-Smirnov (with Lillierfors correction) test. For the rest of variables, two-tailed nonparametric Mann-Whitney U test was used. *P-value < .05. The bold values in the table represent the values reaching statistical significance (P-value < .05). Analyses carried out in WB: protein expression, determined by western blot in PBMC (WBc: in cytoplasmatic fraction; WBn: in nuclear fraction); sol: plasma levels of soluble compounds; act: activity assay in nuclear extracts. See Methods for details.